- Home
- LOMA vs NVCR Comparison
LOMA vs NVCR Comparison
Compare LOMA & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LOMA | NVCR |
|---|---|---|
| Founded | 1926 | 2000 |
| Country | Argentina | Switzerland |
| Employees | N/A | N/A |
| Industry | Building Materials | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2017 | 2015 |
Fundamental Metrics
Financial Performance| Metric | LOMA | NVCR |
|---|---|---|
| Price | $11.22 | $18.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $15.00 | ★ $28.08 |
| AVG Volume (30 Days) | 363.6K | ★ 1.8M |
| Earning Date | 05-04-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $655,353,000.00 |
| Revenue This Year | $27.53 | $7.72 |
| Revenue Next Year | N/A | $6.74 |
| P/E Ratio | $187.97 | ★ N/A |
| Revenue Growth | N/A | ★ 8.28 |
| 52 Week Low | $7.04 | $9.82 |
| 52 Week High | $14.17 | $20.05 |
Technical Indicators
Market Signals| Indicator | LOMA | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 54.26 | 66.39 |
| Support Level | $10.47 | $12.66 |
| Resistance Level | $11.94 | $18.92 |
| Average True Range (ATR) | 0.54 | 0.93 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 55.29 | 72.16 |
Price Performance
Historical ComparisonAbout LOMA Loma Negra Compania Industrial Argentina Sociedad Anonima ADS
Loma Negra Cia Industria Argentina SA is a cement producer in Argentina. The company operates in five segments: Cement, masonry cement, and lime; Concrete; Rail services; Aggregates; and Others. The majority of its revenue derives from Cement, masonry cement, and lime segments.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.